placeholder
and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Proceed order?

Export
Filter
Document type
Language
Year
  • 1
    Language: English
    In: Medicina (Kaunas, Lithuania), 2021-02-05, Vol.57 (2), p.141
    Description: Osteosarcomas (OSs) are a group of neoplasms originating from bone cells, usually presenting in three specific age groups: children, young adults, and the elderly. High-grade OS is an extremely malignant tumor mainly due to evolution into metastatic disease, usually in the lungs. Survival of these patients has improved since the 1980s thanks to close cooperation between oncologists, oncological surgeons and orthopedic surgeons. Unfortunately, no progress has been made in the last 30 years and new, more effective drugs are needed. This article reviews the biological and pharmacological basis of the treatment of OS. Models of clinical pharmacology of the active drugs, toxic effects and reasons for primary and secondary resistance to old and new drugs are discussed.
    Subject(s): Index Medicus ; chemotherapy ; osteosarcoma ; resistance ; pharmacology ; target therapy
    ISSN: 1648-9144
    E-ISSN: 1648-9144
    Source: PubMed Central
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Journal of clinical oncology, 2012-03-20, Vol.30 (9), p.914-920
    Description: To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)-positive chordomas. In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. The primary end point was the overall tumor response rate (ORR), defined by RECIST. Secondary, exploratory end points included tissue response (ie, changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] uptake), overall survival, progression-free survival (PFS), and pain score. Among 50 patients evaluable by RECIST, the best response was one partial response (PR) obtained at 6 months (ORR, 2%). There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate (ie, RECIST complete response + PR + SD ≥ 6 months). A minor dimensional response (〈 20%) was detected in nine patients. A maximum standard uptake value decrease ≥ 25% was observed in 10 (39%) of 26 patients evaluable for PET response at 3 months. Changes in the Brief Pain Inventory score were consistent with the response assessment. Median PFS (intention-to-treat population, 56 patients) was 9 months. No unexpected toxicities were observed. This is the largest phase II study in chordoma to date. It confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.
    Subject(s): Biological and medical sciences ; Medical sciences ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Tumors ; Immunoprecipitation ; Prospective Studies ; Humans ; Middle Aged ; Male ; Antineoplastic Agents - therapeutic use ; Chordoma - pathology ; Immunoenzyme Techniques ; Young Adult ; Aged, 80 and over ; Adult ; Female ; Chordoma - drug therapy ; Receptor, Platelet-Derived Growth Factor beta - metabolism ; Survival Rate ; Treatment Outcome ; Piperazines - therapeutic use ; Imatinib Mesylate ; Switzerland ; Blotting, Western ; Pyrimidines - therapeutic use ; Italy ; Aged ; Benzamides ; Chordoma - mortality
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Journal of clinical oncology, 2012-06-10, Vol.30 (17), p.2112-2118
    Description: We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity. Patients age ≤ 40 years randomly received regimens with the same cumulative doses of drugs (ADM 420 mg/m(2), MTX 120 g/m(2), CDP 600 mg/m(2), and IFO 30 g/m(2)) but with different durations (arm A, 44 weeks; arm B, 34 weeks). IFO was given postoperatively when pathologic response to MTX-CDP-ADM was poor (arm A) or given in the primary phase of chemotherapy with MTX-CDP-ADM (arm B). End points of the study included pathologic response to preoperative chemotherapy, toxicity, and survival. Given the feasibility of accrual, the statistical plan only permitted detection of a 15% difference in 5-year overall survival (OS). From April 2001 to December 2006, 246 patients were enrolled. Two hundred thirty patients (94%) underwent limb salvage surgery (arm A, 92%; arm B, 96%; P = .5). Chemotherapy-induced necrosis was good in 45% of patients (48% in arm A, 42% in arm B; P = .3). Four patients died of treatment-related toxicity (arm A, n = 1; arm B, n = 3). A significantly higher incidence of hematologic toxicity was reported in arm B. With a median follow-up of 66 months (range, 1 to 104 months), 5-year OS and event-free survival (EFS) rates were not significantly different between arm A and arm B, with OS being 73% (95% CI, 65% to 81%) in arm A and 74% (95% CI, 66% to 82%) in arm B and EFS being 64% (95% CI, 56% to 73%) in arm A and 55% (95% CI, 46% to 64%) in arm B. IFO added to MTX, CDP, and ADM from the preoperative phase does not improve the good responder rate and increases hematologic toxicity. IFO should only be considered in patients who have a poor histologic response to MTX, CDP, and ADM.
    Subject(s): Biological and medical sciences ; Medical sciences ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Tumors ; Osteosarcoma - drug therapy ; Femur - pathology ; Humans ; Child, Preschool ; Male ; Tibia - pathology ; Cisplatin - administration & dosage ; Humerus - pathology ; Disease-Free Survival ; Ifosfamide - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy, Adjuvant - methods ; Adolescent ; Adult ; Female ; Methotrexate - administration & dosage ; Bone Neoplasms - drug therapy ; Child ; Doxorubicin - administration & dosage
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Journal of clinical oncology, 2012-03-10, Vol.30 (8), p.850-856
    Description: A previous randomized clinical trial by the Italian Sarcoma Group (ISG) had shown a survival benefit of adjuvant chemotherapy (CT) in high-risk extremity soft tissue sarcoma (STS). However, the dose-intensity of the last two cycles was suboptimal. We then undertook a multicentric international phase III study to compare three and five cycles of the same CT. Patients were randomly assigned either to receive three cycles of preoperative CT with epirubicin 120 mg/m(2) and ifosfamide 9 g/m(2) and granulocyte colony-stimulating factor (arm A) or to receive the same three cycles of preoperative CT followed by two further cycles of postoperative CT (arm B). Noninferiority of the primary end point, overall survival (OS), was assessed by the CI of the hazard ratio (HR; arm A/arm B) obtained from the Cox model. Between January 2002 and April 2007, 328 patients were recruited (164 patients in each arm). At a median follow-up of 63 months (interquartile range, 49 to 77 months), 100 deaths were recorded, 49 in arm A and 51 in arm B. Five-year OS probability was 0.70 for the entire group of patients (0.68 in arm A and 0.71 in arm B). The HR of arm A versus arm B was 1.00 (90% CI, 0.72 to 1.39). In this population of patients with high-risk localized STS, three cycles of full-dose preoperative CT were not inferior to five cycles. The outcome compares favorably with the expected survival of patients with high-risk STS and was superimposable on the CT arm of the previous ISG trial.
    Subject(s): Tumors of the skin and soft tissue. Premalignant lesions ; Biological and medical sciences ; Medical sciences ; Dermatology ; Tumors ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Soft Tissue Neoplasms - mortality ; Drug Administration Schedule ; Follow-Up Studies ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Soft Tissue Neoplasms - drug therapy ; Antineoplastic Agents, Alkylating - administration & dosage ; Epirubicin - administration & dosage ; Sarcoma - drug therapy ; Spain ; Antibiotics, Antineoplastic - administration & dosage ; Ifosfamide - administration & dosage ; Adolescent ; Sarcoma - mortality ; Adult ; Italy ; Aged ; Chemotherapy, Adjuvant ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Index Medicus
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Journal of clinical oncology, 2005-12-01, Vol.23 (34), p.8845-8852
    Description: To explore the effect of high-dose ifosfamide in first-line treatment for patients 〈 or = 40 years of age with nonmetastatic osteosarcoma of the extremity. From March 1997 to September 2000, 182 patients were evaluated. Primary treatment consisted of two blocks of high-dose ifosfamide (15 g/m2), methotrexate (12 g/m2), cisplatin (120 mg/m2), and doxorubicin (75 mg/m2). Postoperatively, patients received two cycles of doxorubicin (90 mg/m2), and three cycles each of high-dose ifosfamide, methotrexate, and cisplatin (120 to 150 mg/m2). Granulocyte colony-stimulating factor support was mandatory after the high-dose ifosfamide/cisplatin/doxorubicin combination. No disease progression was recorded during primary chemotherapy, 164 patients (92%) underwent limb-salvage surgery, four patients (2%) underwent rotation plasty, and 11 patients (6%) had limbs amputated. Three (1.6%) patients died as a result of treatment-related toxicity, and one died as a result of pulmonary embolism after pathologic fracture. Grade 4 neutropenia and thrombocytopenia followed 52% and 31% of all courses, respectively, and mild to severe nephrotoxicity was recorded in 19 patients (10%). The median received dose-intensity compared with protocol was 0.82. With a median follow-up of 55 months, the 5-year probability of event-free survival was 64% (95% CI, 57% to 71%) and overall survival was 77% (95% CI, 67% to 81%), whereas seven patients (4%) experienced local recurrence. The addition of high-dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosfamide. Italian Sarcoma Group/Scandinavian Sarcoma Group study I showed that in a multicenter setting, more than 90% of patients with osteosarcoma of the extremity can undergo conservative surgery.
    Subject(s): Biological and medical sciences ; Chemotherapy ; Medical sciences ; Antineoplastic agents ; Pharmacology. Drug treatments ; Tumors ; Prospective Studies ; Bone Neoplasms - therapy ; Follow-Up Studies ; Humans ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Child, Preschool ; Male ; Bone Neoplasms - pathology ; Cisplatin - administration & dosage ; Dose-Response Relationship, Drug ; Renal Insufficiency - chemically induced ; Adult ; Female ; Child ; Extremities ; Doxorubicin - administration & dosage ; Ifosfamide - adverse effects ; Neoplasm Recurrence, Local ; Treatment Outcome ; Scandinavian and Nordic Countries ; Disease-Free Survival ; Methotrexate - adverse effects ; Ifosfamide - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Adolescent ; Cisplatin - adverse effects ; Italy ; Methotrexate - administration & dosage ; Patient Compliance ; Osteosarcoma - therapy ; Doxorubicin - adverse effects ; Heart Failure - chemically induced ; Osteosarcoma - pathology ; Clinical Medicine ; Medical and Health Sciences ; Klinisk medicin ; Cancer and Oncology ; Medicin och hälsovetenskap ; Cancer och onkologi
    ISSN: 0732-183X
    ISSN: 1527-7755
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Cancer immunology, immunotherapy, 2020-09, Vol.69 (9), p.1905-1916
    Description: Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastatic tumor, with a relatively unpredictable clinical course. A retrospective series of 46 GCTB and a control group of 24 aneurysmal bone cysts (ABC) were selected with the aim of investigating the PD-L1 expression levels and immune-related gene expression profile, in correlation with clinicopathological features. PD-L1 and Ki67 were immunohistochemically tested in each case. Furthermore, comprehensive molecular analyses were carried out using NanoString technology and nCounter PanCancer Immune Profiling Panel, and the gene expression results were correlated with clinicopathological characteristics. PD-L1 expression was observed in 13/46 (28.3%) GCTB (and in 1/24, 4.2%, control ABC, only) and associated with a shorter disease free interval according to univariate analysis. Moreover, in PD-L1-positive lesions, three genes (CD27, CD6 and IL10) were significantly upregulated (p 〈 0.01), while two were downregulated (LCK and TLR8, showing borderline significance, p = 0.06). Interestingly, these genes can be related to maturation and immune tolerance of bone tissue microenvironment, suggesting a more immature/anergic phenotype of giant cell tumors. Our findings suggest that PD-L1 immunoreactivity may help to select GCTB patients with a higher risk of recurrence who could potentially benefit from immune checkpoint blockade.
    Subject(s): Bone and Bones - pathology ; Prognosis ; Giant Cell Tumors - immunology ; Humans ; Middle Aged ; Giant Cell Tumors - pathology ; Male ; Up-Regulation - genetics ; Bone Neoplasms - immunology ; Transcriptome - immunology ; B7-H1 Antigen - genetics ; Bone Neoplasms - pathology ; Down-Regulation - genetics ; Neoplasm Recurrence, Local - pathology ; Young Adult ; Adolescent ; Giant Cell Tumors - genetics ; Immune Tolerance - genetics ; Adult ; Female ; Neoplasm Recurrence, Local - genetics ; Aged ; Biomarkers, Tumor - genetics ; Bone Neoplasms - genetics ; Index Medicus
    ISSN: 0340-7004
    E-ISSN: 1432-0851
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Journal of surgical oncology, 2020-03-15, Vol.121 (4), p.630-637
    Description: Background and Objectives Limb salvage surgery remains the standard treatment in bone and soft tissue tumors. Toronto Extremity Salvage Score (TESS) is the most used quality of life measure. Our objective was to perform cross‐cultural adaptation and validation in Italian, testing test‐retest reliability, construct validity, and responsiveness. Methods We interviewed patients already treated for content validity. A total of 124 patients completed TESS and other questionnaires presurgery, at 3 months, 3 months + 2 weeks, and 6 months follow‐up. We calculated intraclass correlation coefficients (ICCs) for reliability, associations with Pearson's r, and change over time with paired T tests. Results A new item regarding touch‐screen devices was added to the upper extremity (UE) questionnaire. ICC resulted of 0.99 for lower extremity (LE) and 0.98 for UE patients, Pearson's r between TESS and Musculoskeletal Tumor Society was .66 and .64, EuroQol‐5D‐5L r was .62 and .61, and r between TESS and short form‐36 physical function subscale was .76 and .71 for LE and UE groups, respectively. Paired T test results were statistically significant to detect change over time (0.03, 0.04, and 0.04 for LE groups and 0.03, 0.01, and 0.04 for UE groups). Conclusion The Italian version of TESS can be used for the bone and soft tissue sarcoma population in clinical trials in Italy and with Italian speaking patients abroad to ensure patients’ perspectives for efficacy and efficiency of treatments.
    Subject(s): limb salvage ; Italian ; questionnaire ; sarcoma ; quality of life ; TESS ; Extremities - surgery ; Humans ; Middle Aged ; Male ; Sarcoma - psychology ; Bone Neoplasms - pathology ; Young Adult ; Language ; Aged, 80 and over ; Translating ; Adult ; Female ; Surveys and Questionnaires ; Severity of Illness Index ; Bone Neoplasms - psychology ; Limb Salvage - methods ; Reproducibility of Results ; Osteosarcoma - psychology ; Limb Salvage - psychology ; Extremities - pathology ; Bone Neoplasms - surgery ; Sarcoma - pathology ; Cross-Cultural Comparison ; Osteosarcoma - surgery ; Sarcoma - surgery ; Adolescent ; Quality of Life ; Italy ; Aged ; Osteosarcoma - pathology ; Quality of life ; Tumors ; Index Medicus
    ISSN: 0022-4790
    E-ISSN: 1096-9098
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: British journal of cancer, 2017-10-24, Vol.117 (9), p.1278-1285
    Description: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. Patients received oral dovitinib 500 mg day , 5 days on/2 days off, until GIST progression or unacceptable toxicity, with an objective to evaluate efficacy, assessed as the disease control rate (DCR) at 12 weeks. Tumour assessment and response to dovitinib therapy were evaluated by Response Evaluation Criteria In Solid Tumours (RECIST v1.1) and the Choi criteria. Secondary objectives included assessment of progression-free survival (PFS), safety and tolerability, and DCR at the end of treatment. Thirty-eight of the 39 patients enrolled had histologically confirmed GIST. The DCR at 12 weeks was 52.6% (90% confidence interval (CI), 38.2-66.7%) meeting the preset efficacy criterion for the primary end point. The objective response rate (complete response+partial response) was 2.6% (1 of 38; 90% CI, 0.1-11.9%), and 5.3% (n=2; 90% CI, 0.9-15.7%) at the end of the study. The median PFS was 4.6 months (90% CI, 2.8-7.4 months). Dose interruption was required in 26 patients (66.7%), of which 18 (69.2%) were due to adverse events. The most frequently observed grade 3 adverse events included hypertension (n=7), fatigue (n=5), vomiting (n=4), hypertriglyceridaemia (n=4), and γ-glutamyltransferase increase (n=4). Dovitinib is an active treatment for patients with GIST who are intolerant to imatinib or whose GIST progresses on imatinib.
    Subject(s): Prognosis ; Follow-Up Studies ; Gastrointestinal Neoplasms - drug therapy ; Imatinib Mesylate - pharmacology ; Humans ; Middle Aged ; Salvage Therapy ; Male ; Quinolones - pharmacology ; Gastrointestinal Neoplasms - pathology ; Gastrointestinal Stromal Tumors - drug therapy ; Gastrointestinal Stromal Tumors - pathology ; Biomarkers, Tumor - metabolism ; Adult ; Benzimidazoles - pharmacology ; Female ; Gastrointestinal Stromal Tumors - metabolism ; Aged ; Protein Kinase Inhibitors - pharmacology ; Neoplasm Staging ; Drug Resistance, Neoplasm - drug effects ; Gastrointestinal Neoplasms - metabolism ; Life Sciences ; Benzimidazoles/pharmacology ; Biomarkers, Tumor/metabolism ; Drug resistance, Neoplasm/drug therapy ; Gastrointestinal Stromal Tumors ; Cancer ; refractory ; imatinib ; GIST ; dovitinib ; Clinical Study ; gastrointestinal stromal tumour
    ISSN: 0007-0920
    E-ISSN: 1532-1827
    Source: Nature Open Access
    Source: Nature Journals Online
    Source: PubMed Central
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Journal of clinical oncology, 2003-02-15, Vol.21 (4), p.710-715
    Description: To identify factors that influence postrelapse survival (PRS) in patients with nonmetastatic osteosarcoma of the extremity. One hundred sixty-two patients with recurrent osteosarcoma of the extremity were retrospectively reviewed. The first-line treatment included surgery of the primary lesion and chemotherapy with methotrexate, doxorubicin, cisplatin, and ifosfamide. The projected 5-year PRS rate was 28%. Patients who had complete surgery of recurrence had a 5-year PRS of 39%, whereas for those who did not have complete surgery, PRS was 0% at 3 years (P 〈.0001). In the latter group, PRS was not influenced by site of recurrence and relapse-free interval (RFI), although it was influenced (P =.006) by the use of second-line chemotherapy (PRS, 53% at 12 months for patients who received chemotherapy v 12% for those who did not). In patients who had complete surgery, PRS was influenced by site of relapse (5-year PRS, lung 44%, other 19%; P 〈.06), RFI (5-year PRS at 〈 or = 24 months, 20%; at 〉 24 months, 60%; P 〈.0001), and number of lung metastases (5-year PRS, two or fewer nodules, 59%; more than two nodules, 14%; P 〈.0001) but not by the use of a second-line chemotherapy treatment. RFI, site of metastases, and number of pulmonary nodules are the main prognostic factors for PRS in osteosarcoma. Complete surgery of recurrence is pivotal in the strategy of treatment. Patients with unresectable recurrence benefit from second-line chemotherapy, whereas our data do not support a generalized use of chemotherapy after complete surgery of first recurrence.
    Subject(s): Biological and medical sciences ; Medical sciences ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Osteosarcoma - drug therapy ; Bone Neoplasms - mortality ; Confidence Intervals ; Osteosarcoma - mortality ; Prognosis ; Lung Neoplasms - mortality ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Child, Preschool ; Antineoplastic Agents - therapeutic use ; Bone Neoplasms - pathology ; Lung Neoplasms - secondary ; Adolescent ; Adult ; Lung Neoplasms - surgery ; Retrospective Studies ; Bone Neoplasms - drug therapy ; Child ; Osteosarcoma - pathology ; Index Medicus
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Journal of clinical oncology, 2001-03-01, Vol.19 (5), p.1238-1247
    Description: Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results. The present study was designed with restricted selection criteria and high dose-intensities of the two most active chemotherapeutic agents. Patients between 18 and 65 years of age with grade 3 to 4 spindle-cell sarcomas (primary diameter 〉 or = 5 cm or any size recurrent tumor) in extremities or girdles were eligible. Stratification was by primary versus recurrent tumors and by tumor diameter greater than or equal to 10 cm versus less than 10 cm. One hundred four patients were randomized, 51 to the control group and 53 to the treatment group (five cycles of 4'-epidoxorubicin 60 mg/m(2) days 1 and 2 and ifosfamide 1.8 g/m(2) days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor). After a median follow-up of 59 months, 60 patients had relapsed and 48 died (28 and 20 in the treatment arm and 32 and 28 in the control arm, respectively). The median disease-free survival (DFS) was 48 months in the treatment group and 16 months in the control group (P =.04); and the median overall survival (OS) was 75 months for treated and 46 months for untreated patients (P =.03). For OS, the absolute benefit deriving from chemotherapy was 13% at 2 years and increased to 19% at 4 years (P =.04). Intensified adjuvant chemotherapy had a positive impact on the DFS and OS of patients with high-risk extremity soft tissue sarcomas at a median follow-up of 59 months. Therefore, our data favor an intensified treatment in similar cases. Although cure is still difficult to achieve, a significant delay in death is worthwhile, also considering the short duration of treatment and the absence of toxic deaths.
    Subject(s): Biological and medical sciences ; Chemotherapy ; Medical sciences ; Antineoplastic agents ; Pharmacology. Drug treatments ; Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage ; Humans ; Middle Aged ; Soft Tissue Neoplasms - drug therapy ; Male ; Treatment Outcome ; Epirubicin - administration & dosage ; Sarcoma - drug therapy ; Sarcoma - pathology ; Dose-Response Relationship, Drug ; Disease-Free Survival ; Ifosfamide - administration & dosage ; Soft Tissue Neoplasms - surgery ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Sarcoma - surgery ; Adolescent ; Soft Tissue Neoplasms - pathology ; Adult ; Female ; Aged ; Chemotherapy, Adjuvant ; Mesna - administration & dosage
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...